Immune Checkpoint Inhibitor-Associated Thrombotic Thrombocytopenic Purpura in a Patient With Metastatic Non-Small-Cell Lung Cancer
| Autor: | Samantha De Filippis, Amar H Kelkar, Kristin Ezell, Colton Moore, Kunal Aggarwal |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Acquired Thrombotic Thrombocytopenic Purpura Thrombotic microangiopathy business.industry medicine.medical_treatment General Engineering Thrombotic thrombocytopenic purpura Hematology Pembrolizumab medicine.disease thrombotic microangiopathy immune checkpoint inhibitors immune related adverse events Oncology Maintenance therapy Chemoimmunotherapy hemic and lymphatic diseases Internal medicine Internal Medicine medicine Plasmapheresis pembrolizumab thrombotic thrombocytopenic purpura Lung cancer business |
| Zdroj: | Cureus |
| ISSN: | 2168-8184 |
| DOI: | 10.7759/cureus.16035 |
| Popis: | Background: Immune-related adverse events (irAEs) are secondary reactions related to treatment with immune checkpoint inhibitors (ICIs). There have been six cases published reporting on an association between patients undergoing treatment with ICIs and the occurrence of acquired thrombotic thrombocytopenic purpura (TTP). Case report: We report a 61-year-old male receiving treatment with chemoimmunotherapy followed by pembrolizumab maintenance therapy for advanced non-small-cell lung cancer, presenting with bleeding symptoms, anemia, and thrombocytopenia. The patient received pembrolizumab seven times in total, in three-week cycles. Laboratory testing demonstrated hemolytic anemia, which, in combination with other findings, suggested thrombotic microangiopathy (TMA). PLASMIC scoring and specialized testing with ADAMTS13 activity and inhibitor confirmed a diagnosis of TTP. The patient was started on therapy with plasmapheresis and glucocorticoids, resulting in clinical improvement. The patient chose to leave the hospital under the care of home hospice and died approximately one month after being discharged. Conclusions: Of the six cases of ICI-induced TTP, only one other was treated with pembrolizumab to our knowledge to date. Our patient experienced an adverse reaction marked by thrombocytopenia and hematuria after drug exposure. With symptom improvement after ICI discontinuation and recurrence on readministration, a presumptive diagnosis of ICI-associated TTP was made. This case report and literature review emphasize the need for close observation of patients undergoing ICI therapy for potential rare irAEs. The further investigation aimed at the study of risk factors, disease severity, and treatment response to this form of secondary TTP is needed to guide treatment decisions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|